SG11202006255UA - Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability - Google Patents
Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeabilityInfo
- Publication number
- SG11202006255UA SG11202006255UA SG11202006255UA SG11202006255UA SG11202006255UA SG 11202006255U A SG11202006255U A SG 11202006255UA SG 11202006255U A SG11202006255U A SG 11202006255UA SG 11202006255U A SG11202006255U A SG 11202006255UA SG 11202006255U A SG11202006255U A SG 11202006255UA
- Authority
- SG
- Singapore
- Prior art keywords
- intraocular
- medicine
- preventing
- disease associated
- vascular permeability
- Prior art date
Links
- 206010029113 Neovascularisation Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 230000008728 vascular permeability Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018016911 | 2018-02-02 | ||
| PCT/JP2019/003573 WO2019151470A1 (ja) | 2018-02-02 | 2019-02-01 | 眼内血管新生及び／又は眼内血管透過性亢進を伴う眼科疾患の予防又は治療のための医薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202006255UA true SG11202006255UA (en) | 2020-07-29 |
Family
ID=67479734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202006255UA SG11202006255UA (en) | 2018-02-02 | 2019-02-01 | Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20210113529A1 (es) |
| EP (1) | EP3747471A4 (es) |
| JP (1) | JPWO2019151470A1 (es) |
| KR (1) | KR20200116953A (es) |
| CN (1) | CN111683682A (es) |
| AU (1) | AU2019214265A1 (es) |
| BR (1) | BR112020015567A2 (es) |
| CA (1) | CA3089952A1 (es) |
| IL (1) | IL275603A (es) |
| JO (1) | JOP20200186A1 (es) |
| MA (1) | MA53098A (es) |
| MX (1) | MX2020007948A (es) |
| PH (1) | PH12020551015A1 (es) |
| RU (1) | RU2020128700A (es) |
| SG (1) | SG11202006255UA (es) |
| WO (1) | WO2019151470A1 (es) |
| ZA (1) | ZA202004327B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021148439A1 (en) * | 2020-01-21 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for stimulating cerebrovascular function |
| WO2021163355A1 (en) * | 2020-02-11 | 2021-08-19 | Arena Pharmaceuticals, Inc. | Formulations and methods of treating conditions related to the s1p1 receptor |
| IL298996A (en) * | 2020-06-11 | 2023-02-01 | Univ Columbia | Methods and preparations for the prevention and treatment of myopia (myopia) with pingolimod, a sphingosine-1-phosphate receptor modulator, and their derivatives |
| CN113082031A (zh) * | 2021-03-09 | 2021-07-09 | 温州医科大学附属眼视光医院 | 一种多巴胺d1和d2受体非选择性激动剂在作为制备治疗眼部病理性血管新生药物的应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2529318C (en) * | 2003-06-24 | 2013-09-17 | University Of Connecticut | Methods of inhibiting vascular permeability and apoptosis |
| US7794713B2 (en) | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
| JP4993407B2 (ja) | 2004-08-04 | 2012-08-08 | 大正製薬株式会社 | トリアゾール誘導体 |
| GB0504544D0 (en) * | 2005-03-04 | 2005-04-13 | Novartis Ag | Organic compounds |
| CN101415691B (zh) | 2006-02-03 | 2011-12-14 | 大正制药株式会社 | 三唑衍生物 |
| EP1988081B1 (en) | 2006-02-06 | 2012-10-17 | Taisho Pharmaceutical Co., Ltd | Binding inhibitor of sphingosine-1-phosphate |
| PL2003132T3 (pl) | 2006-04-03 | 2014-10-31 | Astellas Pharma Inc | Pochodne oksadiazolu jako agoniści S1P1 |
| US8444970B2 (en) | 2006-10-27 | 2013-05-21 | Lpath, Inc. | Compositions and methods for treating ocular diseases and conditions |
| US20100111963A1 (en) | 2006-11-10 | 2010-05-06 | Genentech, Inc. | Method for treating age-related macular degeneration |
| EP2014653A1 (en) * | 2007-06-15 | 2009-01-14 | Bioprojet | Novel dicarboxylic acid derivatives as S1P1 receptor agonists |
| US8048898B2 (en) | 2007-08-01 | 2011-11-01 | Taisho Pharmaceutical Co., Ltd | Inhibitor of binding of S1P1 |
| PL2354134T3 (pl) | 2008-12-05 | 2016-07-29 | Astellas Pharma Inc | Pochodne 2h-chromenowe jako stymulatory receptora 1-fosforanu sfingozyny |
| CN102686574A (zh) | 2009-10-23 | 2012-09-19 | 阿勒根公司 | 作为具有治疗应用的受体调节剂的香豆素化合物 |
| NZ599966A (en) | 2009-11-24 | 2014-09-26 | Allergan Inc | Novel compounds as receptor modulators with therapeutic utility |
| US20120301478A1 (en) | 2010-01-14 | 2012-11-29 | Yuichiro Ogura | Pharmaceutical for Preventing or Treating Disorders Accompanied by Ocular Angiogenesis and/or Elevated Ocular Vascular Permeability |
| US8273776B2 (en) | 2010-04-16 | 2012-09-25 | Allergan, Inc | Biphenyl oxadiazole derivatives as sphingosine-1-phosphate receptors modulators |
| WO2012071186A1 (en) | 2010-11-24 | 2012-05-31 | Allergan, Inc. | Modulators of s1p receptors |
| CN103380112A (zh) | 2010-11-24 | 2013-10-30 | 阿勒根公司 | 作为s1p受体调节剂的吲哚衍生物 |
| WO2012074921A1 (en) | 2010-12-03 | 2012-06-07 | Allergan, Inc. | Alkyne and alkene derivatives as sphingosine 1-phosphate-1 receptor modulators |
| WO2012105610A1 (ja) | 2011-02-02 | 2012-08-09 | 公立大学法人名古屋市立大学 | 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬 |
| EP2697195A1 (en) | 2011-04-14 | 2014-02-19 | Allergan, Inc. | Phenyl bicyclic methyl azetidine derivatives as sphingosine-1 phosphate receptors modulators |
| CA2833545A1 (en) | 2011-04-18 | 2012-10-26 | Allergan, Inc. | Substituted bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators |
| US9000016B2 (en) | 2012-11-05 | 2015-04-07 | Allergan, Inc. | 1,3,4-Oxadiazoles-2-thio derivatives as sphingosine-1 phosphate receptors modulators |
| US8735433B1 (en) | 2012-11-14 | 2014-05-27 | Allergan, Inc. | Aryl oxadiazole derivatives as sphingosine 1-phosphate (S1P) receptor modulators |
| WO2014130565A1 (en) | 2013-02-20 | 2014-08-28 | Allergan, Inc. | Substituted diaryl azetidine derivatives as sphingosine receptor modulators |
| EP2990055B1 (en) * | 2013-04-26 | 2019-06-05 | Kyoto University | Composition comprising a sphingosine-1-phosphate receptor 1 agonist for inhibiting formation and/or enlargement of cerebral aneurysm or for shrinking it |
| JP2018016911A (ja) | 2016-07-28 | 2018-02-01 | 村田機械株式会社 | 解析装置 |
-
2019
- 2019-02-01 JO JOP/2020/0186A patent/JOP20200186A1/ar unknown
- 2019-02-01 JP JP2019569604A patent/JPWO2019151470A1/ja active Pending
- 2019-02-01 CN CN201980010708.6A patent/CN111683682A/zh active Pending
- 2019-02-01 CA CA3089952A patent/CA3089952A1/en active Pending
- 2019-02-01 KR KR1020207024569A patent/KR20200116953A/ko not_active Application Discontinuation
- 2019-02-01 RU RU2020128700A patent/RU2020128700A/ru unknown
- 2019-02-01 AU AU2019214265A patent/AU2019214265A1/en not_active Abandoned
- 2019-02-01 BR BR112020015567-5A patent/BR112020015567A2/pt not_active IP Right Cessation
- 2019-02-01 US US16/966,757 patent/US20210113529A1/en not_active Abandoned
- 2019-02-01 EP EP19747229.3A patent/EP3747471A4/en not_active Withdrawn
- 2019-02-01 MA MA053098A patent/MA53098A/fr unknown
- 2019-02-01 MX MX2020007948A patent/MX2020007948A/es unknown
- 2019-02-01 WO PCT/JP2019/003573 patent/WO2019151470A1/ja unknown
- 2019-02-01 SG SG11202006255UA patent/SG11202006255UA/en unknown
-
2020
- 2020-06-23 IL IL275603A patent/IL275603A/en unknown
- 2020-06-29 PH PH12020551015A patent/PH12020551015A1/en unknown
- 2020-07-14 ZA ZA2020/04327A patent/ZA202004327B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3747471A1 (en) | 2020-12-09 |
| IL275603A (en) | 2020-08-31 |
| MA53098A (fr) | 2021-05-12 |
| ZA202004327B (en) | 2022-01-26 |
| WO2019151470A1 (ja) | 2019-08-08 |
| RU2020128700A3 (es) | 2022-03-02 |
| JOP20200186A1 (ar) | 2020-07-29 |
| MX2020007948A (es) | 2020-12-10 |
| CN111683682A (zh) | 2020-09-18 |
| JPWO2019151470A1 (ja) | 2021-02-25 |
| PH12020551015A1 (en) | 2021-09-06 |
| AU2019214265A1 (en) | 2020-07-23 |
| KR20200116953A (ko) | 2020-10-13 |
| EP3747471A4 (en) | 2021-10-27 |
| BR112020015567A2 (pt) | 2021-02-02 |
| CA3089952A1 (en) | 2019-08-08 |
| US20210113529A1 (en) | 2021-04-22 |
| RU2020128700A (ru) | 2022-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202004327B (en) | Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability | |
| EP3749264C0 (en) | LASER THERAPY FOR TREATMENT AND PREVENTION OF EYE DISEASES | |
| HUE065585T2 (hu) | Integrált sebészeti rendszer a szem szivárványhártya-szaruhártya szögletének kezelésére | |
| IL268327A (en) | A pharmaceutical preparation for use in the treatment and prevention of c5-related diseases and methods for the treatment and prevention of c5-related diseases | |
| IL281773A (en) | Eye preparation for the treatment of dry eye disease | |
| IL277557A (en) | Self-assembling peptidomimetics and peptidomimetics for the treatment of eye diseases | |
| IL284344A (en) | Pharmaceutical preparations for the eyes and methods for the treatment of diseases of the surface of the eye | |
| EP3405159A4 (en) | TREATMENT AND PREVENTION OF RETINAL VASCULAR DISEASE BY PHOTOCOAGULATION | |
| IL269083A (en) | Methods for the prevention and treatment of heart diseases | |
| EP3481411A4 (en) | TREATING GLAUCOMA AND OTHER EYE DISEASES | |
| IL282504A (en) | Ocular formulations for drug administration and protection of the front part of the eye | |
| IL289405A (en) | Personalized treatment of eye diseases | |
| IL269698B (en) | Methods for preventing or treating eye diseases | |
| MX2017005522A (es) | Tratamiento novedoso de la cornea usando laminina. | |
| LT3949971T (lt) | Liuteolin-7-o-gliukozido arba liuteolin-7-o-gliukuronido panaudojimas vaisto, skirto akių pažeidimamas gydyti, gamyboje | |
| EP3691654A4 (en) | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF EYE SURFACE DISEASES | |
| SG11202012473UA (en) | Ophthalmic compositions and methods for the treatment of eye disorders | |
| SG11202102411WA (en) | Simulated sclera and simulated eyeball | |
| IL282898A (en) | Ophthalmic compounds and methods for treating skin and eye diseases | |
| IL280588A (en) | Ophthalmic compositions and methods for treating eye problems and skin diseases | |
| IL279164A (en) | Corneal implant | |
| RS64066B1 (sr) | Nutriceutička oftalmološka kompozicija za lečenje patoloških stanja retine koja imaju neovaskularnu komponentu | |
| GB201914516D0 (en) | Treatment of eye disease | |
| SG11202005278PA (en) | Compounds for treating eye diseases and methods thereof | |
| IL291522A (en) | Anti-nrp1a antibodies and their uses for the treatment of eyes or eye diseases |